Lung Cancer, Node Tumor Tissue Available, Operated With Curative Intent, Primary Tumor Tissue Available, Stage IIIA-cN2
Conditions
Keywords
NSCLC, N2, molecular profile, prognosis
Brief summary
Mediastinal lymph node (LN) involvement (N2) in non-small cell lung cancer (NSCLC) concerns 15% of resectable tumors and is associated with a poor prognosis and an overall survival reaching 9 to 49%. Literature fails to provide any definitive consensus regarding the management of these patients, except for the platinum-based doublet chemotherapy. The N2 involvement remains a matter of debate because of its not yet well-classified heterogeneity. Regarding anatomy, the Mountain and Dresler's regional LN classification for lung cancer staging remains the reference. Different studies classified IIIA-N2 disease into 4 groups, in addition to the skip-N2 phenomenon: minimal-N2, N2 single station, N2 multiple stations, and bulky-N2. Other subgroups were recently proposed for the 8th edition of the TNM: N2a1 - single station skip, N2a2 - single station non-skip, N2b - multiple stations. The French National Cancer Institute (INCa) proposed guidelines, but in case of cN2 staging without mediastinal infiltration, guidelines remained imprecise (resectability should be discussed for each case) and suggested surgery first, or induction chemotherapy, or concomitant chemoradiation. Thus, optimal management of cIIIA-N2 remains controversial but complete tumor resection can be related to long-term survival in some patients, including 10 years after surgery \[1\]. In this situation, the identification of markers that will help select IIIA-N2 patients who will benefit from surgical resection is mandatory.
Detailed description
We planned a comprehensive molecular characterization of tumors and lymph nodes to evaluate the impact of molecular signatures and molecular heterogeneity on disease-free survival after surgery in IIIA-N2 NSCLC patients. Identification of specific molecular profiles in primary tumors and evolution profiles in nodes might provide clues to the potential risk of metastatic evolution and trigger specific management. For patients included prospectively, we planned to analyze cell free circulating tumor DNA (ctDNA) as prognostic marker. Because multiple biopsies are not always available in care settings, ctDNA could also be analyzed as a surrogate marker of molecular heterogeneity. Next generation sequencing (NGS) that was validated in our lab to screen ctDNA using a specific bio-informatics workflow allows accurate and cost effective ctDNA screening
Interventions
None listed
Sponsors
National Cancer Institute, France
Ministry of Health, France
Université de Paris
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patient, men and women age \>18 years * Patients operated with a curative intent for an IIIA-cN2 NSCLC * Social security affiliation * Written informed consent for patient included in part 2 (prospective) or not opposing the use of this data for patient included in part 1 (retrospective)
Exclusion criteria
* Patient with T4, R1 or R2 surgical resection, sublobar resection, no radical lymphadenectomy * Patient under protectives measures * Pregnancy or breast-feeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-year disease-free survival | 3 years | To identify a molecular signature based on a comprehensive molecular analysis at genomic and transcriptomic levels linked to 3-year disease-free survival in resected IIIA-N2 NSCLC. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 5-year disease-free survival | 5 years | To identify a molecular signature based on a comprehensive molecular analysis at genomic and transcriptomic levels linked to 5-year disease-free survival in resected IIIA-N2 NSCLC. |
| pathological architectural patterns WHO 2015 classification | 5 years | To evaluate the impact of the pathological architectural patterns WHO 2015 classification on the 5-year cancer-specific survival and the 5-year overall survival |
| anatomical lymphatic spread | at the end of molecular analyses | To identify tumor molecular patterns associated with specific anatomical lymphatic spread subgroups. |
| ctDNA | 3 years | To assess ctDNA prognostic impact, before and after surgery. |
Countries
France
Contacts
Primary ContactAntoine LEGRAS, MD PhD
Backup ContactLiliane HAMMANI-BERKANI, MSc
Outcome results
None listed